

Attachment C. National HIV Prevention Program Monitoring and Evaluations (NHM&E) (OMB 0920-0696, Exp. 2/2018)
 Variables No Longer Required (N=109)

Variable Number	Variable Name	Variable Definition
CDC03	CDC Variable 3	This field is reserved for use within the MSM Testing Initiative Project. The specifications are to be determined (TBD).
CDC04	CDC Variable 4	This field is reserved for use within the MSM Testing Initiative Project. The specifications are to be determined (TBD).
CDC05	CDC Variable 5	This field is reserved for use within the MSM Testing Initiative Project. The specifications are to be determined (TBD).
H01	Intervention ID	An alpha-numeric identification code used to uniquely identify an intervention.
H01a	Intervention Name	The unique name of the intervention as defined by the agency.
H01b	Program Evidence Base	The name of a Program Evidence Base.
H01c	Specify Other Program Evidence Base	A name of a Program Evidence Base if 3.01 - Study / Special Study (specify) or 3.02-Other (specify) was selected in H01b.
H02	Number of Planned Sessions	The total number of sessions planned for an intervention. The number of planned sessions can differ depending on the needs of individual clients (e.g., CRCS).
H05	Number of Completed Sessions	The number of sessions that were completed by the client for a particular intervention.
H07	Date of enrollment	The calendar month, day, and year on which the client enrolls in the intervention.
H08	Program ID	A unique alpha-numeric identification number used to identify a program.
H08a	Program Name	The unique name of the program as defined by the agency.
ME100a	Program Delivery Year	The year which the HIV prevention program was delivered or implemented, and for which aggregate level data are being reported.
ME100b	Program Delivery Period	The 6-month period during which the HIV prevention program was delivered or implemented, and for which aggregate level data are being reported.
ME101	Number of HIV-diagnosed clients linked to HIV medical care	The number of HIV-diagnosed clients who were linked to HIV medical care. Linkage to HIV medical care occurs when a client attends a routine HIV medical care visit within 3 months of HIV diagnosis.
ME101a	Number of HIV-diagnosed MSM/IDU linked to HIV medical care	The number of HIV-diagnosed MSM/IDU who were linked to HIV medical care. Linkage to HIV medical care occurs when a client attends a routine HIV medical care visit within 3 months of HIV diagnosis.

ME101b	Number of HIV-diagnosed MSM linked to HIV medical care	The number of HIV-diagnosed MSM who were linked to HIV medical care. Linkage to HIV medical care occurs when a client attends a routine HIV medical care visit within 3 months of HIV diagnosis.
ME101c	Number of HIV-diagnosed IDU linked to HIV medical care	The number of HIV-diagnosed IDU who were linked to HIV medical care. Linkage to HIV medical care occurs when a client attends a routine HIV medical care visit within 3 months of HIV diagnosis.
ME101d	Number of HIV-diagnosed heterosexuals linked to HIV medical care	The number of HIV-diagnosed heterosexuals who were linked to HIV medical care. Linkage to HIV medical care occurs when a client attends a routine HIV medical care visit within 3 months of HIV diagnosis.
ME101e	Number of HIV-diagnosed clients with other/unknown behavioral risk factors linked to HIV medical care	The number of HIV-diagnosed clients with other behavioral risks (i.e., excluding MSM, IDU, or heterosexual) or unknown behavioral risks who were linked to HIV medical care. Linkage to HIV medical care occurs when a client attends a routine HIV medical care visit within 3 months of HIV diagnosis.
ME101f	Number of HIV-diagnosed African Americans linked to HIV medical care	The number of HIV-diagnosed non-Hispanic blacks or African Americans who were linked to HIV medical care. Linkage to HIV medical care occurs when a client attends a routine HIV medical care visit within 3 months of HIV diagnosis.
ME101g	Number of HIV-diagnosed Hispanics linked to HIV medical care	The number of HIV-diagnosed Hispanics/Latinos of any race who were linked to HIV medical care. Linkage to HIV medical care occurs when a client attends a routine HIV medical care visit within 3 months of HIV diagnosis.
ME101h	Number of HIV-diagnosed clients of other race/ethnicity linked to HIV medical care	The number of HIV-diagnosed clients with a race/ethnicity other than black/African American, Hispanic/Latino, or unknown who were linked to HIV medical care. Linkage to HIV medical care occurs when a client attends a routine HIV medical care visit within 3 months of HIV diagnosis.
ME102	Number of HIV-diagnosed clients linked to treatment adherence services	The number of HIV-diagnosed clients who were linked to anti-retroviral treatment (ART) adherence services. Medication adherence is defined as the extent to which patients follow medical regimens as prescribed by their health care providers.
ME102a	Number of HIV-diagnosed MSM/IDU linked to treatment adherence services	The number of HIV-diagnosed MSM/IDU who were linked to anti-retroviral treatment (ART) adherence services. Medication adherence is defined as the extent to which patients follow medical regimens as prescribed by their health care providers.

ME102b	Number of HIV-diagnosed MSM linked to treatment adherence services	The number of HIV-diagnosed MSM who were linked to anti-retroviral treatment (ART) adherence services. Medication adherence is defined as the extent to which patients follow medical regimens as prescribed by their health care providers.
ME102c	Number of HIV-diagnosed IDU linked to treatment adherence services	The number of HIV-diagnosed IDU who were linked to anti-retroviral treatment (ART) adherence services. Medication adherence is defined as the extent to which patients follow medical regimens as prescribed by their health care providers.
ME102d	Number of HIV-diagnosed heterosexuals linked to treatment adherence services	The number of HIV-diagnosed heterosexuals who were linked to anti-retroviral treatment (ART) adherence services. Medication adherence is defined as the extent to which patients follow medical regimens as prescribed by their health care providers.
ME102e	Number of HIV-diagnosed clients with other/unknown behavioral risk factors linked to treatment adherence services	The number of HIV-diagnosed clients with other behavioral risks (i.e., excluding MSM, IDU, or heterosexual) or unknown behavioral risks who were linked to anti-retroviral treatment (ART) adherence services. Medication adherence is defined as the extent to which patients follow medical regimens as prescribed by their health care providers.
ME102f	Number of HIV-diagnosed African Americans linked to treatment adherence services	The number of HIV-diagnosed non-Hispanic blacks or African Americans who were linked to anti-retroviral treatment (ART) adherence services. Medication adherence is defined as the extent to which patients follow medical regimens as prescribed by their health care providers.
ME102g	Number of HIV-diagnosed Hispanics linked to treatment adherence services	The number of HIV-diagnosed Hispanics/Latinos of any race who were linked to anti-retroviral treatment (ART) adherence services. Medication adherence is defined as the extent to which patients follow medical regimens as prescribed by their health care providers.
ME102h	Number of HIV-diagnosed clients of another race/ethnicity linked to treatment adherence services	The number of HIV-diagnosed clients with a race/ethnicity other than black/African American, Hispanic/Latino, or unknown who were linked to anti-retroviral treatment (ART) adherence services. Medication adherence is defined as the extent to which patients follow medical regimens as prescribed by their health care providers.
ME103	Number of out-of-care HIV-diagnosed clients re-engaged into HIV medical care and treatment services	The number of out-of-care HIV-diagnosed clients who were re-engaged into HIV medical care and treatment services. Re-engagement in HIV medical care is defined as the process of assisting persons with HIV to resume HIV medical care after a lapse in care.

ME103a	Numbers of out-of-care HIV-diagnosed MSM/IDU re-engaged into HIV medical care and treatment services	The number of out-of-care HIV-diagnosed MSM/IDU who were re-engaged into HIV medical care and treatment services. Reengagement in HIV medical care is defined as the process of assisting persons with HIV to resume HIV medical care after a lapse in care.
ME103b	Numbers of out-of-care HIV-diagnosed MSM re-engaged into HIV medical care and treatment services	The number of out-of-care HIV-diagnosed MSM who were re-engaged into HIV medical care and treatment services. Reengagement in HIV medical care is defined as the process of assisting persons with HIV to resume HIV medical care after a lapse in care.
ME103c	Numbers of out-of-care HIV-diagnosed IDU re-engaged into HIV medical care and treatment services	The number of out-of-care HIV-diagnosed IDU who were re-engaged into HIV medical care and treatment services. Reengagement in HIV medical care is defined as the process of assisting persons with HIV to resume HIV medical care after a lapse in care.
ME103d	Numbers of out-of-care HIV-diagnosed heterosexuals re-engaged into HIV medical care and treatment services	The number of out-of-care HIV-diagnosed heterosexuals who were re-engaged into HIV medical care and treatment services. Reengagement in HIV medical care is defined as the process of assisting persons with HIV to resume HIV medical care after a lapse in care.
ME103e	Number of out-of-care HIV-diagnosed clients with other/unknown behavioral risk factors re-engaged into HIV medical care and treatment services	The number of out-of-care HIV-diagnosed clients with other behavioral risks (i.e., excluding MSM, IDU, or heterosexual) or unknown behavioral risks, who were re-engaged into HIV medical care and treatment services. Reengagement in HIV medical care is defined as the process of assisting persons with HIV to resume HIV medical care after a lapse in care.
ME103f	Numbers of out-of-care HIV-diagnosed African Americans re-engaged into HIV medical care and treatment services	The number of out-of-care HIV-diagnosed non-Hispanic blacks or African Americans who were re-engaged into HIV medical care and treatment services. Reengagement in HIV medical care is defined as the process of assisting persons with HIV to resume HIV medical care after a lapse in care.
ME103g	Numbers of out-of-care HIV-diagnosed Hispanics re-engaged into HIV medical care and treatment services	The number of out-of-care HIV-diagnosed Hispanics/Latinos of any race who were re-engaged into HIV medical care and treatment services. Reengagement in HIV medical care is defined as the process of assisting persons with HIV to resume HIV medical care after a lapse in care.
ME103h	Number of out-of-care HIV-diagnosed clients of another race/ethnicity re-engaged into HIV medical care and treatment services	The number of out-of-care HIV-diagnosed clients with a race/ethnicity other than black/African American, Hispanic, or unknown, who were re-engaged into HIV medical care and treatment services. Reengagement in HIV medical care is defined as the process of assisting persons with HIV to resume HIV medical care after a lapse in care.
ME104	Number of condoms distributed	The total number of condoms distributed.

ME105a	Number of condoms distributed to high-risk individuals who are HIV-negative or whose HIV status is unknown	The estimated number of condoms distributed to high-risk HIV-negative individuals and high-risk individuals whose HIV status is unknown.
ME105b	Number of condoms distributed to HIV positive individuals	The estimated number of condoms distributed to HIV-positive clients.
ME109	Number of community EBI conducted	The total number of community-level evidence-based interventions (EBI) conducted. A community EBI is defined as an EBI that seeks to improve the risk conditions and behaviors in a community through a focus on the community as a whole.
ME110	Number of people reached by community EBIs	The estimated total number of high-risk HIV-negative individuals that accessed or were reached by (i.e., exposed) community evidence-based interventions (EBIs). A community EBI is defined as an EBI that seeks to improve the risk conditions and behaviors in a community through a focus on the community as a whole.
ME111	Number of social marketing/public information conducted	The total number of social marketing/public information events conducted. Social marketing/public information events are defined as HIV-prevention messages delivered through one or more mass communication channels to target audiences.
ME112	Number of people reached by social marketing/public information events	The estimated total number of people exposed to a key message disseminated by social marketing /public information events. Exposure to a marketing campaign occurs when a person views or hears a key message disseminated by the campaign.
ME113	Number of media placements for marketing campaigns	The total number of media placements for marketing campaigns. A media placement is the use of various types of media to promote or advertise a particular message. HIV/AIDS-related media placements may be produced in a variety of formats.
ME114	Number of clients referred to non-occupational PEP therapy	The number of clients who were referred to non-occupational post-exposure prophylaxis (PEP) therapy. PEP involves the medically-supervised provision of HIV antiretroviral drugs (ART) to HIV-negative persons who may have recently been exposed to HIV.
ME114a	Number of MSM/IDU referred to non-occupational PEP therapy	The number of MSM/IDU referred to non-occupational Post-Exposure Prophylaxis (PEP) therapy. PEP involves the medically-supervised provision of HIV antiretroviral drugs (ART) to HIV-negative persons who may have recently been exposed to HIV.

ME114b	Number of MSM referred to non-occupational PEP therapy	The number of MSM referred to non-occupational Post-Exposure Prophylaxis (PEP) therapy. PEP involves the medically-supervised provision of HIV antiretroviral drugs (ART) to HIV-negative persons who may have recently been exposed to HIV.
ME114c	Number of IDU referred to non-occupational PEP therapy	The number of IDU referred to non-occupational Post-Exposure Prophylaxis (PEP) therapy. PEP involves the medically-supervised provision of HIV antiretroviral drugs (ART) to HIV-negative persons who may have recently been exposed to HIV.
ME114d	Number of high-risk heterosexuals referred to non-occupational PEP therapy	The number of high-risk heterosexuals referred to non-occupational Post-Exposure Prophylaxis (PEP) therapy. PEP involves the medically-supervised provision of HIV antiretroviral drugs (ART) to HIV-negative persons who may have recently been exposed to HIV.
ME114e	Number of clients with other or unknown risks referred to non-occupational PEP therapy	The number of clients with other behavioral risks (i.e., excluding MSM, IDU, or high-risk heterosexuals) or unknown behavioral risks referred to non-occupational Post-Exposure Prophylaxis (PEP) therapy. PEP involves the medically-supervised provision of HIV antiretroviral drugs (ART) to HIV-negative persons who may have recently been exposed to HIV.
ME114f	Number of African Americans referred to non-occupational PEP therapy	The number of non-Hispanic blacks or African Americans referred to non-occupational Post-Exposure Prophylaxis (PEP) therapy. PEP involves the medically-supervised provision of HIV antiretroviral drugs (ART) to HIV-negative persons who may have recently been exposed to HIV.
ME114g	Number of Hispanics referred to non-occupational PEP therapy	The number of Hispanics/Latinos of any race referred to non-occupational Post-Exposure Prophylaxis (PEP) therapy. PEP involves the medically-supervised provision of HIV antiretroviral drugs (ART) to HIV-negative persons who may have recently been exposed to HIV.
ME114h	Number of clients of another race/ethnicity referred to non-occupational PEP therapy	The number of clients with a race/ethnicity other than blacks/African Americans or Hispanics, or clients of unknown race/ethnicity referred to non-occupational Post-Exposure Prophylaxis (PEP) therapy. PEP involves the medically-supervised provision of HIV antiretroviral drugs (ART) to HIV-negative persons who may have recently been exposed to HIV.
ME115	Number of clients initiated non-occupational PEP therapy	The number of clients who were referred to and initiated non-occupational post-exposure prophylaxis (PEP) therapy. PEP involves the medically-supervised provision of HIV antiretroviral drugs (ART) to HIV-negative persons who may have recently been exposed to HIV.

ME115a	Number of MSM/IDU who initiated non-occupational PEP therapy	The number of MSM/IDU who were referred and initiated non-occupational Post-Exposure Prophylaxis (PEP) therapy. PEP involves the medically-supervised provision of HIV antiretroviral drugs (ART) to HIV-negative persons who may have recently been exposed to HIV.
ME115b	Number of MSM who initiated non-occupational PEP therapy	The number of MSM who were referred and initiated non-occupational Post-Exposure Prophylaxis (PEP) therapy. PEP involves the medically-supervised provision of HIV antiretroviral drugs (ART) to HIV-negative persons who may have recently been exposed to HIV.
ME115c	Number of IDU who initiated non-occupational PEP therapy	The number of IDU who were referred and initiated non-occupational Post-Exposure Prophylaxis (PEP) therapy. PEP involves the medically-supervised provision of HIV antiretroviral drugs (ART) to HIV-negative persons who may have recently been exposed to HIV.
ME115d	Number of high-risk heterosexuals who initiated non-occupational PEP therapy	The number of high-risk heterosexuals who were referred and initiated non-occupational Post-Exposure Prophylaxis (PEP) therapy. PEP involves the medically-supervised provision of HIV antiretroviral drugs (ART) to HIV-negative persons who may have recently been exposed to HIV.
ME115e	Number of clients with other or unknown risks who initiated non-occupational PEP therapy	The number of clients with other behavioral risks (i.e., excluding MSM, IDU, or high-risk heterosexuals) or unknown behavioral risks who were referred to and initiated non-occupational Post-Exposure Prophylaxis (PEP) therapy. PEP involves the medically-supervised provision of HIV antiretroviral drugs (ART) to HIV-negative persons who may have recently been exposed to HIV.
ME115f	Number of African American who initiated non-occupational PEP therapy	The number of non-Hispanic blacks or African Americans who were referred to and initiated non-occupational Post-Exposure Prophylaxis (PEP) therapy. PEP involves the medically-supervised provision of HIV antiretroviral drugs (ART) to HIV-negative persons who may have recently been exposed to HIV.
ME115g	Number of Hispanics who initiated non-occupational PEP therapy	The number of Hispanics/Latinos of any race who were referred to and initiated non-occupational Post-Exposure Prophylaxis (PEP) therapy. PEP involves the medically-supervised provision of HIV antiretroviral drugs (ART) to HIV-negative persons who may have recently been exposed to HIV.
ME115h	Number of clients of another race/ethnicity who initiated non-occupational PEP therapy	The number of clients with a race/ethnicity other than blacks/African Americans or Hispanics, or clients of unknown race/ethnicity who were referred to and initiated non-occupational Post-Exposure Prophylaxis (PEP) therapy. PEP involves the medically-supervised provision of HIV antiretroviral drugs (ART) to HIV-negative persons who may have recently been exposed to HIV.

ME116	Number of MSM referred to PrEP therapy	The number of MSM referred to pre-exposure prophylaxis (PrEP) therapy. PrEP may be part of comprehensive HIV prevention services in which HIV-negative individuals at high risk for HIV infection take antiretroviral medication daily to lower the risk of HIV infection.
ME116a	Number of African American MSM referred to PrEP therapy	The number of high-risk non-Hispanic black or African American MSM referred to Pre-Exposure Prophylaxis (PrEP) therapy. PrEP may be part of comprehensive HIV prevention services in which HIV-negative individuals at high risk for HIV infection take antiretroviral medication daily to lower the risk of HIV infection.
ME116b	Number of Hispanic MSM referred to PrEP therapy	The number of Hispanic/Latino MSM of any race referred to Pre-Exposure Prophylaxis (PrEP) therapy. PrEP may be part of comprehensive HIV prevention services in which HIV-negative individuals at high risk for HIV infection take antiretroviral medication daily to lower the risk of HIV infection.
ME116c	Number of MSM of another or unknown race/ethnicity referred to PrEP therapy	The number of MSM clients with a race/ethnicity other than black/African American or Hispanic, or MSM clients of unknown race/ethnicity referred to Pre-Exposure Prophylaxis (PrEP) therapy. PrEP may be part of comprehensive HIV prevention services in which HIV-negative individuals at high risk for HIV infection take antiretroviral medication daily to lower the risk of HIV infection.
ME117	Number of MSM initiated PrEP therapy	The number of MSM who were referred to and initiated pre-exposure prophylaxis (PrEP) therapy. PrEP may be part of comprehensive HIV prevention services in which HIV-negative individuals at high risk for HIV infection take antiretroviral medication daily to lower the risk of HIV infection.
ME117a	Number of African American MSM who initiated PrEP therapy	The number of non-Hispanic blacks or African Americans MSM who were referred and initiated Pre-Exposure Prophylaxis (PrEP) therapy. PrEP may be part of comprehensive HIV prevention services in which HIV-negative individuals at high risk for HIV infection take antiretroviral medication daily to lower the risk of HIV infection.
ME117b	Number of Hispanic/Latino MSM who initiated PrEP therapy	The number of Hispanics/Latinos of any race MSM who were referred and initiated Pre-Exposure Prophylaxis (PrEP) therapy. PrEP may be part of comprehensive HIV prevention services in which HIV-negative individuals at high risk for HIV infection take antiretroviral medication daily to lower the risk of HIV infection.
ME117c	Number of MSM of another or unknown race/ethnicity initiated PrEP therapy	The number of MSM clients with a race/ethnicity other than black/African American or Hispanic, or MSM clients of unknown race/ethnicity who were referred and initiated Pre-Exposure Prophylaxis (PrEP) therapy. PrEP may be part of comprehensive HIV prevention services in which HIV-negative individuals at high risk for HIV infection take antiretroviral medication daily to lower the risk of HIV infection.

ME203a	Category B total PS12-1201-funded aggregate test events	PS12-1201-funded aggregate test events are test events supported in any way by PS12-1201-funded resources (e.g., funding, test kits, personnel, training and technical assistance, laboratory support), but for which test-level data are not obtainable.
ME203b	Category B total reimbursed aggregate test events	Reimbursed aggregate test events are test events that are done in PS12-1201-supported programs, but are actually paid for by a third-party payer (e.g., Medicaid, Medicare, private insurance).
ME204a	Category B PS12-1201-funded aggregate newly diagnosed HIV-positive test events	PS12-1201-funded aggregate test events are test events supported in any way by PS12-1201-funded resources (e.g., funding, test kits, personnel, training and technical assistance, laboratory support), but for which test-level data are not obtainable.
ME204b	Category B reimbursed aggregate newly diagnosed HIV-positive testing events	Reimbursed aggregate test events are test events that are done in PS12-1201-supported programs, but are actually paid for by a third-party payer (e.g., Medicaid, Medicare, private insurance).
ME207a	Number of syphilis tests conducted as part of service integration in healthcare settings	The number of syphilis tests conducted under service integration for PS12-1201 Category B in healthcare settings. Service integration is a situation in which a person is offered and can receive two or more CDC-recommended prevention, treatment, or care services.
ME207b	Number of syphilis tests conducted under service integration in non-healthcare settings	The number of syphilis tests conducted under service integration for PS12-1201 Category B in non-healthcare settings. Service integration is a situation in which a person is offered and can receive two or more CDC-recommended prevention, treatment, or care services.
ME208a	Number of gonorrhea tests conducted under service integration in healthcare settings	The number of gonorrhea tests conducted under service integration for PS12-1201 Category B in healthcare settings. Service integration is a situation in which a person is offered and can receive two or more CDC-recommended prevention, treatment, or care services.
ME208b	Number of gonorrhea tests conducted under service integration in non-healthcare settings	The number of gonorrhea tests conducted under service integration for PS12-1201 Category B in non-healthcare settings. Service integration is a situation in which a person is offered and can receive two or more CDC-recommended prevention, treatment, or care services.

ME209a	Number of chlamydia tests conducted under service integration in healthcare settings	The number of tests for chlamydial infection conducted under service integration for PS12-1201 Category B in healthcare settings. Service integration is a situation in which a person is offered and can receive two or more CDC-recommended prevention, treatment, or care services.
ME209b	Number of chlamydia tests conducted under service integration in non-healthcare settings	The number of tests for chlamydial infection conducted under service integration for PS12-1201 Category B in non-healthcare settings. Service integration is a situation in which a person is offered and can receive two or more CDC-recommended prevention, treatment, or care services.
ME210a	Number of tests for hepatitis B virus conducted under service integration in healthcare settings	The number of tests for hepatitis B virus (HBV) conducted under service integration for PS12-1201 Category B in healthcare settings. Service integration is a situation in which a person is offered and can receive two or more CDC-recommended prevention, treatment, or care services.
ME210b	Number of tests for hepatitis B virus conducted under service integration in non-healthcare settings	The number of tests for hepatitis B virus (HBV) conducted under service integration for PS12-1201 Category B in non-healthcare settings. Service integration is a situation in which a person is offered and can receive two or more CDC-recommended prevention, treatment, or care services.
ME211a	Number of tests for hepatitis C virus conducted under service integration in healthcare settings	The number of tests for hepatitis C virus (HCV) conducted under service integration for PS12-1201 Category B in healthcare settings. Service integration is a situation in which a person is offered and can receive two or more CDC-recommended prevention, treatment, or care services.
ME211b	Number of tests for hepatitis C virus conducted under service integration in non-healthcare settings	The number of tests for hepatitis C virus (HCV) conducted as part of service integration for PS12-1201 Category B in non-healthcare settings. Service integration is a situation in which a person is offered and can receive two or more CDC-recommended prevention, treatment, or care services.
ME212a	Number of tuberculosis tests conducted under service integration in healthcare settings	The number of tuberculosis tests conducted as part of service integration for PS 12-1201 Category B in healthcare settings. Service integration is a situation in which a person is offered and can receive two or more CDC-recommended prevention, treatment, or care services.
ME212b	Number of tuberculosis tests conducted under service integration in non-healthcare settings	The number of tuberculosis tests conducted as part of service integration for PS 12-1201 Category B in non-healthcare settings. Service integration is a situation in which a person is offered and can receive two or more CDC-recommended prevention, treatment, or care services.
ME213a-z	Target population of HIV-positive individuals	Targeted HIV-positive populations (e.g., MSM, IDU, transgender) for prevention interventions.

ME214a-z	Total number of HIV-positive persons enrolled in behavioral risk screening	A behavioral risk screen is a brief evaluation of behavioral HIV risk factors used to decide who should be recommended for HIV testing, interventions, or other services.
ME215a-z	Total number of HIV-positive persons enrolled in individual- and group-level evidence-based interventions	The total number of HIV-positive persons from the specified Target Population enrolled in individual- and group-level evidence-based interventions.
ME216a-z	Total number of HIV-positive persons enrolled in community-level evidence-based interventions	The total number of HIV-positive persons from the specified Target Population enrolled in community-level evidence-based interventions.
ME217a-z	Total number of HIV-positive persons enrolled in other locally developed programs	The total number of HIV-positive persons from the specified Target Population enrolled in other locally developed programs.
ME218a-z	Target population of high-risk HIV-negative individuals	Targeted high-risk HIV-negative populations for prevention interventions (e.g., MSM, IDU, high-risk heterosexuals, transgender).
ME219a-z	Total number of high-risk HIV-negative persons enrolled in behavioral risk screening	A behavioral risk screen is a brief evaluation of behavioral HIV risk factors used to decide who should be recommended for HIV testing, interventions, or other services.
ME220a-z	Total number of high-risk HIV-negative persons enrolled in individual- and group-level evidence-based interventions	The total number of high-risk HIV-negative persons from the specified Target Population enrolled in individual- and group-level evidence based interventions.
ME221a-z	Total number of high-risk HIV-negative persons enrolled in community-level evidence-based interventions	A community-level evidence-based intervention (EBI) is defined as an EBI that seeks to improve the risk conditions through a focus on the community as a whole, rather than by interviewing only individuals or small groups.
ME222a-z	Total number of high-risk HIV-negative persons enrolled in other locally developed programs	The total number of high-risk HIV-negative persons from the specified Target Population enrolled in other locally developed programs.
CBOCL001	Date of first visit in this budget year	The date of the client's first visit this budget year
CBOCL002	Budget year	Budget year refers to the PS15-1502 12-month funding period (July 1 - June 30) in which the client received this service.
CBOCL005	Client's HIV Status	The client's self-reported or documented HIV status at the time of his/her first visit this budget year.
CBOCL006	HIV Medical Care	The client's self-report of currently receiving HIV medical care.

CBOCL007	HIV Linked to Medical Care - attended first medical appointment	A client, not currently in HIV medical care, was linked to or re-engaged in HIV medical care - attended first medical appointment.
CBOCL008	Change in HIV Status since the first visit in this budget year	The client's HIV status changed from HIV-negative or unknown to HIV-positive since her/his first visit in this budget year.
CBOCL009	Navigation and prevention and essential support services, RRA	The navigation, prevention, and essential support services that a client was referred to or provided as part of PS15-1502 risk reduction activities.
CBOCL009SP	Other recommended support services, RRA	Description of other navigation and prevention and essential support services a client was referred to or provided.